Sequence similarity between the erythrocyte binding domain of the Plasmodium vivax Duffy binding protein and the V3 loop of HIV-1 strain MN reveals a functional heparin binding motif involved in binding to the Duffy antigen receptor for chemokines by Bolton, Michael J & Garry, Robert F
RESEARCH Open Access
Sequence similarity between the erythrocyte
binding domain of the Plasmodium vivax Duffy
binding protein and the V3 loop of HIV-1 strain
MN reveals a functional heparin binding motif
involved in binding to the Duffy antigen receptor
for chemokines
Michael J Bolton
1,2 and Robert F Garry
1*
Abstract
Background: The HIV surface glycoprotein gp120 (SU, gp120) and the Plasmodium vivax Duffy binding protein
(PvDBP) bind to chemokine receptors during infection and have a site of amino acid sequence similarity in their
binding domains that often includes a heparin binding motif (HBM). Infection by either pathogen has been found
to be inhibited by polyanions.
Results: Specific polyanions that inhibit HIV infection and bind to the V3 loop of X4 strains also inhibited DBP-
mediated infection of erythrocytes and DBP binding to the Duffy Antigen Receptor for Chemokines (DARC). A
peptide including the HBM of PvDBP had similar affinity for heparin as RANTES and V3 loop peptides, and could
be specifically inhibited from heparin binding by the same polyanions that inhibit DBP binding to DARC. However,
some V3 peptides can competitively inhibit RANTES binding to heparin, but not the PvDBP HBM peptide. Three
other members of the DBP family have an HBM sequence that is necessary for erythrocyte binding, however only
the protein which binds to DARC, the P. knowlesi alpha protein, is inhibited by heparin from binding to
erythrocytes. Heparitinase digestion does not affect the binding of DBP to erythrocytes.
Conclusion: The HBMs of DBPs that bind to DARC have similar heparin binding affinities as some V3 loop peptides
and chemokines, are responsible for specific sulfated polysaccharide inhibition of parasite binding and invasion of
red blood cells, and are more likely to bind to negative charges on the receptor than cell surface
glycosaminoglycans.
Introduction
The human immunodeficiency virus type 1 (HIV-1), the
human malaria, Plasmodium vivax,a n dt h em o n k e y
malaria, P. knowlesi, have ligands that bind to chemo-
kine receptors and mediate cell invasion. The surface
glycoprotein gp120 (SU) of HIV-1 binds to CCR5 and
CXCR4 as the major coreceptors for infecting CD4+ T-
lymphocytes in vivo, and changes in the amino acid
sequence of the V3 loop of gp120 can change viral trop-
ism from CCR5 using (R5) to CXCR4 using (X4) to
both (R5X4) [1-4]. The V3 loop region of gp120 also
provides a neutralizing epitope, and can bind glycosami-
noglycans and other polyanions which inhibit viral infec-
tion [5-14].
P. vivax uses a Duffy binding protein (PvDBP) to bind
the Duffy antigen receptor for chemokines (DARC) and
invade human reticulocytes. P. knowlesi has three pro-
teins, the P. knowlesi a, b,a n dg proteins which can
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knowlesi a protein (PkDBP) can bind to human and rhe-
sus DARC. PvDBP, PkDBP, P. knowlesi b, and g proteins
are members of a Duffy Binding Ligand (DBL) family of
erythrocyte binding proteins with conserved regions of
homology which bind to many receptors. Region II
within the family, as defined by conserved cysteine resi-
dues, is responsible for erythrocyte binding, and region
II of PkDBP has been shown to be inhibited by glycosa-
minoglycan binding [15].
In a separate report, we describe an amino acid
sequence similarity between subdomain 1 in DBP region
II and the V3 loop of HIV strain MN [16]. Within sub-
domain 1 and this V3 loop are consensus BBXB heparin
binding motifs (HBM), where B is a basic amino acid
and X is any amino acid. This HBM is conserved in
many DBL family members, and we previously found
that alanine substitutions at this site in PvDBP and
PkDBP abrogated DARC binding. RANTES is a natural
ligand of both CCR5 and DARC and can inhibit both
HIV and DBP binding to their respective receptors.
SDF-1 is a natural ligand for CXCR4, and both RANTES
and SDF-1 have HBM and are known to bind sulfated
polysaccharides [17].
One possible function of the HBM in chemokines, HIV
and DBPs is to associate with cell surface proteoglycans.
Alternatively, HBMs could participate in binding to nega-
tively charged amino acid side chains on the chemokine
receptors. RANTES is known to bind to sulfated polysac-
charides as part of its processing and function, but tyro-
sine sulfation of CCR5 is also important for binding of
chemokines and HIV, and sulfation of Tyr 41 on DARC is
important for DBP binding. He r ew ed e s i g n e dap e p t i d e
from PvDBP subdomain 1 that contains the HBM, tested
its ability to bind sulfated polysaccharides, and compared
it to the binding of the PvDBP, PkDBP, P. knowlesi b and
g proteins, HIV V3 loop peptides and RANTES to see if
they shared similar binding specificities.
Materials and methods
Polyanions
Ca-spirulan, Na-spirulan, and Na-hornan (Na-HOR)
were kindly provided by Toshimutsu Hayashi,
Department of Virology, Toyama Medical and Pharma-
ceutical University, Sugitani, Toyama, Japan [18,19].
Heparin, dextran sulfate, and pentosan polysulfide were
obtained from Sigma-Aldrich (St. Louis, MO).
Peptide preparation
Peptides based on the wild type (wt) putative polyamine
binding site of the PvDBP and a non-binding mutant,
pvR22KARA (Figure 1) were obtained from Gene med
Synthesis, Inc. (San Francisco, CA). The synthesis
included N-terminal fluoresce in conjugation and HULK
purification to greater than 80%. Peptides of the V3
loop were obtained from the NHI AIDS Reagent Pro-
gram (NHI AIDS Reagent Program, Rockville, Md.)
Heparin-sepharose columns
The binding affinity of the PvDBP HBM and V3 loop
peptides for heparin was determined by chromatography
on a heparin-Sepharose column. Heparin-Sepharose CL-
6B beads (Pharmacia Biotech) were swollen in 50 mM
Tris-HCl pH 7.5 (column buffer), degassed for 1 h, and
1 ml of slurry was added to a 10 ml column. The col-
umn was equilibrated with 10 volumes of column buffer.
Peptides were added at 1 mg/ml in 300 μl and allowed
to enter the column. The column was washed with 3 ml
of column buffer. The peptide was eluted with 3 ml
volumes of increasing NaCl concentrations of 0.01, 0.15,
0.5, 1.0 and 2.0 M, and 0.5 ml fractions were collected.
The column was regenerated between peptides by add-
ing alternating 3 ml volumes of 0.1 M Tris-HCl, 0.5 M
N a C l ,p H8 . 5a n d0 . 1MN a O A c ,0 . 5MN a C l ,p H5 . 0
for three cycles. The column was re-equilibrated with 10
vol. of column buffer before adding the next peptide.
Fractions were measured for absorbance at 280 nm on a
spectrophotometer.
P. Knowlesi in vitro culture
Whole blood from rhesus macaques was collected in
10% CPD and allowed to separate overnight at 4°C. The
erythrocyte phase was washed in RPMI with L-gluta-
mine and supplemented with 25 mM HEPES, 300 μM
hypoxanthine, 10 μM thymidine, 1.0 mM sodium pyru-
vate, and 11 mM glucose. This RPMI with malaria
Hbs-wt: FITC-NCNYKRKRRERDWDCNDYKDDDDK
Hbs-kara: FITC-NCNYARKRAEADWDCNDYKDDDDK
Figure 1 Design of peptides hbs-wt and hbs-kara. The consensus heparin binding motif in the DBP V3-like peptide of PvRII is contained in
hbs-wt. The same alanine substitutions from a nonbinding mutant of PvRII (pv22KARA), tested in a previous study, were included in hbs-kara
[16]. Alanine-substituted amino acids are in blue and red. The N-terminus is to the left and is FITC-conjugated. The final residues at the C-
terminus, DYKDDDDK, represent the FLAG epitope and are in bold.
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medium by adding to a final concentration of 0.24%
sodium bicarbonate and 0.2% Albumax-I (Life Tech,
Gibco BRL). Cultures were maintained at a hematocrit
of 10% in malaria culture medium under an atmosphere
of 5% O2,5 %C O 2, balanced N2 (Air Liquide, Houston,
TX) at 38°C.
Erythrocytes
Blood was collected in 10% citrate phosphate dextrose
(CPD) and stored at 4°C unwashed for up to 4 weeks,
or washed in RPMI with malaria supplements and
stored in malaria culture medium at 50% hematocrit for
up to 2 weeks. The DARC+ human erythrocytes used in
the erythrocyte binding assay and the P. knowlesi ery-
throcyte invasion assay had the phenotype Fy(a
-b
+)a s
determined by standard blood banking methods using
anti-Fya and anti-Fyb antisera (Gamma Biologicals,
Houston, TX). Erythrocytes were washed three times in
DMEM (Gibco BRL) and resuspended to a hematocrit
of 10% in complete DMEM for the erythrocyte binding
assay. Erythrocytes used in the P. knowlesi erythrocyte
invasion assay were washed three times and resuspended
to a hematocrit of 10% using malaria complete RPMI.
Percoll purification of schizont-infected erythrocytes
Cultures of P. knowlesi at 5-10% infected erythrocytes
were washed three times in RPMI with malaria supple-
ments and 10% FBS and brought up to a hematocrit of
10%. A 50% Percoll solution was made by adding 0.45
vol 1× PBS, 0.05 vol 10× PBS and 0.5 vol Percoll
(Sigma). Two ml of the washed culture was overlaid on
2 ml of the 50% Percoll solution in a 4 ml polystyrene
tube and centrifuged for 20 min at 2100 RPM in a Sor-
vall centrifuge. The ring of cells at the interface was
removed, pooled and washed three time in 1× PBS. The
pellet was brought up in malaria culture medium to 2 ×
10
7 cells/ml.
P. Knowlesi erythrocyte invasion assay
Human Duffy Fy(a
-b
+) erythrocytes were washed in
complete malaria medium and 2 × 10
7 washed cells
were added to increasing concentrations of sulfated
polysaccharide in malaria culture medium at final
volume of 900 μl for 1 h at room temperature. To each
tube of sulfate polysaccharide-treated erythrocytes, 100
μlo r2×1 0
6 schizont-infected erythrocytes was added
and placed in a well of a polystyrene 24-well plate (Bec-
ton-Dickinson). The cultures were maintained under a
blood-gas atmosphere at 38°C for 8 h to allow the
infected erythrocytes to rupture and release free mero-
zoites capable of infecting new erythrocytes and devel-
oping to ring-stage trophozoites. The culture was
centrifuged at 2100 RPM for 3 min and a thin smear
was made from the pellet. The thin smear was fixed
with methanol and stained with Leukostat Solution B
(100 mg Eosin Y+ 300 μl 37% formaldehyde +400 mg
sodium phosphate dibasic +500 mg potassium phos-
phate monobasic, q.s. to 100 ml with dH2O), rinsed, and
stained with Leukostat Solution C (47 mg Methylene
Blue +44 mpp Azure A +400 mg sodium phosphate
dibasic +500 mg potassium phosphate monobasic, q.s to
100 ml with dH2O). The percentage of erythrocytes
infected with ring-stage trophozoites per 2000 erythro-
cytes was determined at 1000×. Percentage inhibition of
invastion was determined by dividing the percentage of
ring-stage parasites at each polyanion concentration by
the percentage of ring-stage parasites at 0 μg/ml of the
polyanion, multiplying by 100 and subtracting this value
from 100 [20]
PvRII erythrocyte binding assay
COS-7 cells were transfected by Lipofectamine with 1-2
μg of pHVDR22 DNA, a plasmid kindly provided by L.
Miller which expresses region II of the DBP of P. vivax
on the cell surface as a chimera with the HSV gD pro-
tein [21]. Duffy Fy (a-b+) erythrocytes were washed
three times in RPMI 1640, resuspended to a hematocrit
of 1% in 1 ml of complete DMEM with polyanions at
concentrations of 0, 1, 10, 100, and 1000 μg/ml. This
suspension was swirled over aspirated COS-7 cells 40-60
h after transfection and allowed to settle over 2 h at 37°
C. The COS-7 cells were then washed three times with
2 ml of PBS to remove nonadherent erythrocytes. The
number of adherent erythrocyte rosettes was scored in
20 randomly chosen fields at a magnification of 40
using an inverted microscope. Percentage inhibition of
binding was determined by dividing the number of
rosettes at each polyanion concentration by the percen-
tage of rosettes at 0 μg/ml of the polyanion, multiplying
by 100 and subtracting this value from 100.
PvDBP peptide BSA-heparin ELISA
Polyvinyl chloride 96-well microtiter plates were coated
with 5 μg/ml heparin-albumin (Sigma) in a volume of
100 μl per well in 50 mM Tris-HCl pH 7.5 wash buffer
overnight at room temperature. Plates were washed
three times with wash buffer and blocked for 2 h at
room temperature with 1% BSA in wash buffer at 400 ul
per well. For polyanion blocking experiments, WT or
mutant DBP polyanion binding site peptides were
diluted to 10 μg/ml in a final concentration of polya-
nions at 0, 0.1, 1, 10, 100, or 1,000 μg/ml in wash buffer
a n da d d e da t1 0 0μl per well for 2 h. For controls, the
DBP peptides were added at 10 μg/ml in 0.01, 0.15, 0.5,
1.0, and 2.0 M NaCl 50 mM Tris HCl pH 7.5 (data not
shown). Plates were washed three times with wash buf-
fer. Chicken anti-DYKDDDDK epitope antibody (Aves
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at 100 μl per well for 1 h at room temperature. Rabbit
anti-chicken horseradish peroxidase antibody (Jackson
ImmunoResearch) was added at 1:5000 in 1% BSA wash
buffer at 100 μl per well for 1 h at room temperature.
Plates were washed three times with wash buffer. The
reaction was developed with 100 μlp e rw e l lo f2 %
3,3’,5,5’-tetramethylbenzidine 0.1 M NaOAc containing
0.001% hydrogen peroxide for about 5 min. The reaction
was stopped with 100 μl per well of 1 M phosphoric
acid. Absorbance measurements were made at 450 nm
on a Biotek 133 microtiter plate reader. Percentage inhi-
bition of binding was determined by dividing the absor-
bance at each polyanion concentration by the
absorbance at 0 μg/ml of the polyanion, multiplying by
100 and subtracting this value from 100.
RANTES BSA-heparin ELISA
The same ELISA format used for the PvDBP Peptide-
BSA-heparin ELISA described above was used for a
competitive ELISA to detect RANTES binding to
heparin, and competitors to this binding. Wells were
coated with BSA-heparin, blocked with BSA and
washed. A volume of 100 μl of 5 nM RANTES in wash
buffer supplemented with 0, 0.5, 5, 50, 500 or 5000 nM
peptide was added to triplicate wells. After incubation
for 1.5 h at room temperature, the plates were washed
in wash buffer and 100 μl of biotinylated anti-RANTES
monoclonal antibody (R&D Systems) was added at 1:500
in 0.1% BSA wash buffer. After 1 h at room tempera-
ture, the plates were washed and 100 μl of streptavidin-
horseradish peroxidase (Jackson ImmunoResearch) was
added at 1:2000 in 0.1% BSA wash buffer. After 1 h at
room temperature, the plates were washed. The reaction
was developed as above. Percentage inhibition of bind-
ing was determined by dividing the absorbance at each
peptide concentration by the absorbance at 0 nM of the
peptide, multiplying by 100 and subtracting this value
from 100.
Heparitinase digestion
Red blood cells were washed 3 times in PBS and resus-
pended at a hematocrit of 10%. For the PvRII erythro-
cyte binding assay, 1 ml of 10% hct blood was used. To
each 1 ml of red blood cells, 0, 0.001, 0.002 or 0.01
International Units (which correspond to 0.6, 1.2 and 6
Sigma Units, respectively) of Heparitinase (EC 4.2.2.8,
Seikagaku America, Falmouth, MA) was added. The
cells were incubated at 43°C for 90 min. with intermit-
tent agitation. An aliquot of 30 μl of the cells was taken
for analysis by flow cytometry (data not shown). The
remaining cells were then centrifuged at 3000 RPM for
5 min., and resuspended in 1 ml of complete for use in
the PvRII erythrocyte binding assay.
Results
Region II of the P. Vivax DBP is blocked from binding to
DARC by the same polyanions that inhibit X4 HIV strains
Within the DBP V3-like peptide is a site that conforms to
the consensus heparin binding sequences BBXB and
BBBXXB, where B represents a basic amino acid and X
represents any amino acid including basic amino acids.
Some strains of HIV, such as MN, contain a consensus
heparin binding motif in the V3 loop, and many X4 strains
can be inhibited from infecting target cells by polyanions
which may bind to the V3 loop. Polyanions that have been
shown to inhibit HIV infection include pentosan polysul-
fate, heparin, and the algal-derived sulfated polysacchar-
ides Na-spirulan, Ca-spirulan and Na-hornan (Na-HOR)
[18,22]. These polyanions also inhibited the binding of
DARC+ erythrocytes to PvRII in a dose-dependent man-
ner (Figure 2). They also block P. knowlesi invasion of
DARC+ erythrocytes (Figure 3). Chondroitin sulfate C
represents a polyanion with similar charge to heparin, but
differs in the conformational placement of those charges.
Chondroitin sulfate C does not block PvRII binding to
DARC, or P. knowlesi invasion of DARC+ erythrocytes,
suggesting that the interaction between PvRII and polya-
nions is related to conformation as well as charge. The
same is true for inhibition of the V3 loop by polyanions
[5,7-12,14,23-25].
A peptide based on the consensus heparin binding motif
in the DBP V3-like peptide binds to heparin with the
same affinity as V3 loop peptides of X4 HIV strains and
recapitulates polyanion inhibition of PvRII binding to
DARC
A peptide based on the consensus heparin binding motif
in the DBP V3-like peptide was designed to test the affi-
nity of this site for heparin and compare it to V3 loop
peptides and RANTES. Based on results with an alanine
substitution mutant of the consensus heparin binding
motif in the DBP V3-like peptide, two peptides were
designed; one contains the wild type heparin binding
site (hbs-wt), and the other contains the same alanine
substitutions as the pv22KARA construct (hbs-kara)
found in our previous work to abrogate binding to
DARC [16]. The peptides are FITC conjugated at the N-
terminus and terminate at the carboxyl end with the
DYKDDDDK “flag epitope” sequence for fluorescence or
antigenic detection, respectively. They are identical with
the exception of the alanine substitutions (Figure 1).
The hbs-wt, hbs-kara, an assortment of V3 loop pep-
tides, and RANTES were bound to a heparin-Sepharose
column and eluted with 0.01, 0.15, 0.5, 1.0 or 2.0 M
NaCl. The NaCl concentration required to elute the
peptides provides a relative value for the affinity
between the peptide and heparin, and is directly propor-
tional to the Kd value. The 0.15 M NaCl concentration
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Figure 2 Polyanion inhibition of PvRII binding to DARC+ erythrocytes.H e p a r i n ,p e n t o s a np o l y s u l f a t e , and the algal-derived sulfated
polysaccharides Ca-spirulan, and Na-hornan (Na-HOR) have been shown to have potent inhibitory activity against HIV binding and infection.
Chondroitin sulfate C does not and serves as a control. Inhibition of DARC+ erythrocytes binding to the DBP binding site was determined by
comparing the number of COS-7 cells expressing pvRII with rosettes of polyanion-treated DARC+ human erythrocytes (per 20 fields at 200×
magnification) with the number of rosettes of untreated erythrocytes.
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Figure 3 Polyanion inhibition of P. knowlesi invasion of DARC+ erythrocytes. The same polyanions used to inhibit the pvRII binding assay
shown in Figure 2 were used in the P. knowlesi invasion assay. The inhibition of invasion was determined by subtracting the number of
chemokine-treated DARC+ human erythrocytes invaded by P. knowlesi merozoites (per 2000 erythrocytes) from the number of untreated DARC+
human erythrocytes invaded by P. knowlesi merozoites, and dividing by the number of untreated, invaded erythrocytes.
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Page 5 of 11is physiologically relevant but reflects weak binding, 0.5
M indicates moderate binding, and 1.0 M and above
represents strong binding (reviewed in chapter 6 of
“Heparin-Binding Proteins” [26]. Most of the peptides
could be detected in the fractions by their absorbance of
light at 280 nm on a spectrophotometer, with the excep-
tion of the linear V3 loop peptide of strain IIIB that
lacks aromatic side chains. The Pierce BCA Protein
Assay was used to detect this peptide (Figure 4).
The hbs-wt peptide eluted at 0.5 M NaCl (Table 1).
The hbs-kara peptide did not bind to the column at all,
eluting with the wash buffer. In a subsequent experi-
ment, without the wash step, it eluted with 0.01 M
NaCl. The cyclic V3 loop peptide of X4 HIV strain MN
also eluted at 0.5 M as did the linear peptide of X4
strain IIIB. Of the linear peptides that are overlapping
subunits of the MN cyclic peptide, the peptide contain-
ing the consensus heparin binding motif eluted at 1.0
M. This is a stronger interaction than the cyclic full-
length V3 peptide. Other V3 peptides based on consen-
sus sequences of subtypes B and EA, or specific strains
RF and SF2, eluted at 0.15 M. RANTES eluted at 0.5 M.
There was no direct relationship between net charge of
the peptides and affinity to heparin, as the cyclic MN
peptide with a charge of +7 eluted at a lower NaCl con-
centration than the linear peptide at a charge of +6. The
most neutral net charge in the tested group of peptides
was 0 for the hbs-wt, and it eluted at 0.5 M NaCl.
An ELISA based on coating plates with BSA-heparin
and determining the binding of the hbs-wt peptide, or
hbs-kara as a control, was developed. This assay showed
high sensitivity for detecting bound hbs-wt peptide with
low background as demonstrated by low signal pro-
duced by the hbs-kara control (data not shown). The
binding was inhibited at the same NaCl concentrations
that eluted the hbs-wt peptide in the heparin-Sepharose
column at 0.5 M and above (data not shown). When
sulfated polysaccharides were added to the ELISA, they
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Figure 4 Heparin-Sepharose column fractions.P e p t i d e si nT a b l e1w e r eb o u n dt oah e p a r i n - S e p h a r o s ec o l u m na n de l u t e dw i t hN a C la t
concentrations of 0.01, 0.15, 0.5, 1.0, and 2.0 M. The optical densities of the fractions of most peptides were determined in the at a wavelength
of 280 nm. Representative examples of the optical densities of fractions from three peptides in Table 1 are shown in panels A-C in which the
NaCl concentration at which the peak fraction eluted is written above the peak.
Table 1 Heparin-Sepharose peak fractions of peptides of the V3 loop of HIV, hbs-wt and hbs-kara of the P. vivax DBP,
and RANTES
Peptide Amino Acid Sequence Charge @ pH 7.0 [NaCl] of Peak Fraction
Cyclic V3 strain MN CTRPNYNKRKRIDIGPGRAFTTKNIIGTIRQAHC +7 0.5 M
Linear sub-V3 strain MNa CTRPNYNKRKRIHIPGPGRA +6 1.0 M
Linear sub-V3 strain MNb RIHIGPGRAF YTTKNIIGTI +3 0.15 M
Linear sub-V3 strain MNc YTTKNIIPTIRQAHCNISRA +3 0.15 M
Cyclic V3 subtype EA CTSITIGPGQVFYRTGC +1 0.15 M
Cyclic V3 Subtype B CKGIRIPGPRAVYAAEC +2 0.15 M
Linear V3 Strain RF KSITKGPGRVIYATG +3 0.15 M
Linear V3 Strain SF2 KSIFIGPGRAFHTTG +2 0.15 M
Linear V3 Strain IIIB TRPNNNTRKSIRIQRGPGRAFVTIGKIGNMR +8 0.5 M
Hbs-wt NCNYKRKRRERDWDCNDYKDDDDK 0 0.5 M
Hbs-kara NCNYARKAREADWDCNDYKDDDDK- 3 0.01 M
RANTES MKVSAARLAVILIATACAPASASPYSSDTTP
CCFAYIARPLPRAHIKEYFYTSGKCSNPAVV
FVTRKNRQVCANPEKKWVREYINSLEMS +7 0.5 M
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Page 6 of 11inhibited the binding of the hbs-wt peptide in a dose-
dependent manner. The same sulfated polysaccharides
found to be inhibitory in the erythrocyte invasion assay
and the PvRII region binding assay where inhibitory in
the ELISA, with no inhibition from chondroitin sulfate
C. (Figure 5).
V3 loop peptides from HIV-1 strain MN have different
polyanion binding specificities than the DBP subdomain 1
HBM peptide
The heparin affinities of hbs-wt peptide, the cyclic V3
loop peptide of HIV-1 strain MN, and RANTES were
the same when tested in heparin-Sepharose columns,
and X4 strains of HIV, PvRII and hbs-wt can be inhib-
ited by the same polyanions, but not chondroitin sulfate.
To see if there are differences in the specificity by which
the V3 peptides and the hbs-wt peptide bind to heparin,
an ELISA based on RANTES binding to BSA-heparin
was developed much like the hbs-wt ELISA. The only
difference to the hbs-wt ELISA is that RANTES is sub-
stituted for the hbs peptide, and detection is through a
biotinylated mouse anti-RANTES monoclonal antibody
followed by horseradish peroxidase-conjugated streptavi-
din. The V3 loop peptides and hbs peptides were added
at different concentrations to compete with RANTES at
a fixed 5 nM. The linear and cyclic V3 loop peptides of
strain MN that had significant binding on heparin-
S e p h a r o s ew e r ea b l et oc o m p e t ew i t hR A N T E Sb i n d i n g
to BSA-heparin in a dose-dependent manner, but the
hbs-wt peptide was not (Figure 6).
The subdomain 1 HBM has a conserved role in the DBP
protein family for binding to diverse receptors, but only
members of the family that bind to DARC are inhibited
by polyanions
Studies by Ranjan and Chitnis have identified a site in
PvRII in the C-terminal flanking region to the DBP V3-
like peptide, between C4 and C7, that contain residues
necessary for DARC binding [27]. This study also
showed that the C1-C4 region of the P. knowlesi beta
protein, a member of the DBP family that does not bind
to DARC, was capable of substituting for the P. vivax
C1-C4. Upon closer inspection, the consensus heparin
binding motif is well conserved in the DBP family, with
great similarity between proteins that bind different
receptors [16]. The P. knowlesi alpha and gamma pro-
teins have an identical consensus heparin binding site,
b u to n l ya l p h ab i n d st oD A R C .T os e ei ft h ec o n s e n s u s
heparin binding motif may play a similar role in the
binding proteins of other members of the DBP family,
the same three alanine substitutions found in
pv22KARA were introduced in our previous report by
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Figure 5 Polyanion inhibition of the hbs-wt peptide binding to
heparin in the BSA-heparin ELISA. An ELISA was used to
determine the inhibition of the hbs-wt peptide binding to heparin
by various polyanions. The hbs-wt peptide was added to BSA-
heparin coated plates and detected by a horse-radish peroxidase
conjugated antibody that recognizes the FLAG epitope. Polyanions
used to inhibit hbs-wt peptide binding to heparin included those
used in the pvRII binding and P. knowlesi invasion assays. Also
included were dextran sulfate and sodium spirulan which have also
been shown to be potent inhibitors of X4 HIV strains. Percentage
inhibition of binding was determined by dividing the absorbance at
each polyanion concentration by the absorbance at 0 μg/ml of the
polyanion.
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Figure 6 Competitive Inhibition of RANTES-ELISA with V3 loop
and hbs-wt peptides. An ELISA format similar to that in Figure 5
was used to measure RANTES binding to heparin and compare the
ability of various peptides to compete with this binding. A fixed
concentration of 5 nM RANTES was mixed with various
concentrations of competitors before addition to BSA-heparin
coated plates. RANTES was then detected by an anti-RANTES mAb,
a biotinylated secondary antibody and streptavidin conjugated to
horseradish peroxidase. Percentage inhibition of binding was
determined by dividing the absorbance at each peptide
concentration by the absorbance at 0 nM of the peptide.
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Page 7 of 11site directed mutagenesis into the plasmids pHKADR22,
pHKBDR22, and pHKGDR22. This yielded the con-
structs pkalphaKARA, pkbetaKARA, and pkgamma-
KARA, which contain the K221, R224, and R227 alanine
substitution in the P. knowlesi alpha, beta, and gamma
genes, respectively. All three of these mutants failed to
bind rhesus erythrocytes when expressed in COS-7 cells,
w h e r e a st h ep a r e n tv e c t o r sb i n dv e r yw e l l[ 1 6 ] .W h e n
binding of rhesus erythrocytes to the wild type plasmids
in COS-7 cells was measured in the presence of polya-
nions, only the DARC binding alpha protein was inhib-
ited in a dose-dependent manner (Figure 7).
Heparitinase digestion of erythrocytes does not inhibit
PvRII binding to DARC or P. Knowlesi invasion of DARC+
human erythrocytes
To determine if polyanion binding and inhibition of
PvRII was an indication that heparan sulfate on the sur-
face of RBC was required for DARC binding, erythro-
cytes were digested with heparitinase, which specifically
cleaves heparan sulfate. There was no significant differ-
ence in the binding or invasion of cells treated with
increasing concentrations of heparitinase (Figure 8).
Discussion
Members of the Duffy Binding Protein family have been
found to bind to sulfated polysaccharides in a manner
that inhibits their attachment to a variety of cell surface
receptors. HIV can also be inhibited from chemokine
receptor binding by sulfated polysaccharides, a property
that has been the impetus for testing many microbicides
in clinical trials. In a previous study, we examined simi-
larities between the V3 loop of HIV-1 strain MN and
the subdomain 1 of the Duffy Binding Protein of P.
vivax that includes an HBM. This HBM is necessary for
DARC binding and is conserved in the DBP family[16].
RANTES is a natural ligand of both the HIV coreceptor
CCR5 and DARC, blocks binding of HIV and DBPs to
these receptors, respectively, and contains an HBM.
SDF-1 is the natural ligand for the HIV coreceptor
CXCR-4 and contains a HBM. RANTES and SDF-1
bind to proteoglycans as part of their function, but also
require tyrosine sulfation of CCR5 and CXCR-4 for
binding, and their HBM that may function in both roles
[28,29].
We hypothesize that the DBP and SU have conver-
gently evolved to use chemokine receptors for binding,
and may mimic the GAG and/or sulfated tyrosine bind-
ing functions of the chemokines using the V3 loop of
SU and the HBM of subdomain 1 of the DBP. Here, we
compared the binding specificity and affinity of HIV V3
loops, DBPs, a peptide containing the DBP HBM, and
RANTES for binding to sulfated polysaccharides to
assess whether they shared common binding mechan-
isms to chemokine receptors. In our first set of experi-
ments we showed that the same sulfated polysaccharides
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Figure 8 PvRII binding to heparitinase treated DARC+
erythrocytes. DARC+ human erythrocytes were digested with
heparitinase I, an endoglycosidase specific for heparan sulfate. The
number of rosettes of heparitinase-treated erythrocytes on COS-7
cells transfected with the pvRII expression vector, pHVDR22, is
shown as the mean of three separate treatments.
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Figure 7 Heparin inhibition of region II of P. knowlesi EBPs
binding to rhesus erythrocytes. The P. knowlesi alpha, beta and
gamma proteins are members of the DBP family, bind rhesus
erythrocytes by region II, and contain a consensus HBM. Only the
alpha protein binds DARC. The PvRII binding assay shown in Figure
2 was repeated using plasmids to express the P. knowlesi EBPs, and
using rhesus erythrocytes. Inhibition was determined in the same
manner as the PvRII binding assay.
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Page 8 of 11that inhibit HIV binding and infection can also inhibit
P. knowlesi infection of human erythrocytes, which is
mediated by the P. knowlesi DBP binding to DARC.
Using a previously described binding assay, we found
the same sulfated polysaccharides inhibit P. vivax DBP
region II from binding to DARC. In each of these and
subsequent experiments, chondroin sulfate C was used
as a negative control showing that not only the negative
charges of the polysaccharides, but their specific orienta-
tion are important for inhibition.
T os e ei fs u b d o m a i n1o fr e g i o nI Io fP v D B P ,w h i c h
contains the HBM, may be involved in sulfated polysac-
charide inhibition of DARC binding, we explored the
affinity and specificity of a peptide based on this site for
binding to sulfated polysaccharides. We found that a
peptide containing the putative HBM (hbs-wt) does
indeed bind to heparin, with a physiologically significant
affinity similar to that of RANTES. In a previous study,
we substituted alanine at K221, R224, and R227 of the
PvDBP region II, which replaced the HBM and abro-
gated DARC binding [16]. A peptide based on this ala-
nine substitution mutant (hbs-kara) did not bind to
heparin. V3 loops containing an HBM bound with high
affinity to heparin. The binding affinities of these pep-
tides on a heparin-sepharose column were not corre-
lated with their net charge, again suggesting structural
specificity in their binding to sulfated polysaccharides.
We tested the specificity of the subdomain 1 HBM
interaction with sulfated polysaccharides other than
heparin by designing an ELISA in which hbs-wt peptide
binding to heparin-coated wells could be detected. The
same sulfated polysaccharides found to be inhibitory in
the erythrocyte invasion assay and the RII region bind-
ing assay could competitively inhibit the hbs-wt peptide
from binding heparin in the ELISA, with no inhibition
from chondroitin sulfate C. This suggests that there is a
structural interaction between the HBM of subdomain 1
and sulfated polysaccharides that is responsible for inhi-
bition of merozoite invasion. The ELISA format is much
faster than whole-cell and other binding assays and cap-
able of being used as a high-throughput screen for inhi-
bitors of merozoite infection. It may also detect leads
for binding inhibitors of other DBLs and HIV.
We next compared whether the sulfated polysacchar-
ide binding by the subdomain 1 HBM and V3 loops
were structurally similar to that of RANTES. We
developed an ELISA to detect RANTES binding to
heparin and then measured competitive inhibition of
that binding. Only V3 loop peptides containing an
H B Mf r o ms t r a i nM Nc o m p e t e di na ,b u tn o to t h e r
V3 loop peptides or the subdomain 1 peptide. This
was not expected since RANTES binds to CCR5 and
DARC while HIV-1 strain MN does not bind to CCR5,
but to CXCR4.
It is possible that the HBMs of the DBP and V3 loops
and mimic one or both binding properties of chemo-
kines; to glycosaminoglycans (GAGs) or to sulfated tyro-
sines on chemokine receptors. We have shown the
HBM in subdomain 1 can bind to sulfated polysacchar-
ides, but DBP requires sulfation of tyrosine (Tyr 41) on
DARC for binding [30], and the HBM may interact with
this as well. Discrimination of SU between CCR5 and
CXCR4 can be conferred by amino acid changes in the
V3 loop [2,31-34]. The V3 loop is one of four SU
domains that can contribute to heparan sulfate binding
[6,35]. CCR5 and CXCR-4 have amino-terminal
sequences that include tyrosine sulfation that are
believed to be essential for HIV binding and may inter-
act in part with positive residues in V3 HBMs. Here, the
V3 loop of MN may indeed contribute to binding of sul-
fated tyrosines on CXCR-4 but have greater similarity
with RANTES than does subdomain 1 for GAG binding.
We further explored whether the HBM in the DBL
family might have a conserved GAG binding function
by comparing sulfated polysaccharide inhibition of the
PkDBP and the P. knowlesi beta and gamma proteins.
Among these, only PkDBP binds to DARC while the
receptors for the other two proteins are unknown. Only
the PkDBP was inhibited by sulfated polysaccharides,
though in our previous study, alanine substitution of the
HBM abrogated erythrocyte binding of the beta and
gamma proteins. This argues against the HBM serving a
conserved GAG binding function in the DBL family or
of nonspecifically binding to GAGs. When treated with
heparitinase, erythrocytes retain their binding to PvDBP,
also arguing against GAG binding as the function of the
HBM in this protein. We did not digest other cell sur-
face proteoglycans, and though a detection antibody for
heparan sulfate showed loss of signal (data not shown),
it is not possible to know if the digestion was complete
enough to eliminate all interactions with the DBP.
Other members of the DBL family have been shown to
bind heparan sulfate. The P. falciparum erythrocyte
membrane protein (PfEMP) family is expressed on the
surface of parasitized erythrocytes, can mediate erythro-
cyte rosetting and cytoadherence and also contains
Duffy binding like (DBL) domains with many HBMs
[36]. Erythrocyte rosettes can be disrupted by digestion
of heparan sulfate [36,37].
The HBMs of chemokines appear to exhibit multiple
functions, allowing for cell surface binding and extracel-
lular matrix sequestration as well as direct binding to
sulfated tyrosines on chemokine receptors. This polyva-
lency could aid in the sometimes promiscuous binding
between chemokines and chemokine receptors. The
HIV SU, PkDBP and PvDBP have convergently evolved
to bind to chemokine receptors and may use HBM or
positively charged regions to mimic chemokine binding
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Page 9 of 11to GAG or sulfated tyrosines on the chemokine recep-
tors. Sulfated polysaccharides may specifically block
HBM regardless of their role in receptor binding, but
appear to block members of the DBL with either known
GAG or chemokine binding functions. The HBM in
subdomain 1 of the DBP is required for DARC binding
and has specific sulfated polysaccharide binding proper-
ties that recapitulates the inhibition of the merozoites
invading erythrocytes and region II binding to DARC.
This makes the PvDBP HBM an attractive target for
inhibition since it is a conserved motif, and some of the
same inhibitors may block HIV, though there are differ-
ences in heparin binding specificity of the PvDBP HBM
and V3 loops as shown by competitive inhibition of
RANTES binding to heparin. We have developed a high
throughput screen for these inhibitors based on a ELISA
with the PvDBP HBM. NMR structures of heparin bind-
ing to chemokines are available and future studies could
better define the nature of PvDBP interaction with poly-
anionic inhibitors.
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